Sarcopenia in Advanced COPD Affects Cardiometabolic Risk Reduction by Short-Term High-intensity Pulmonary Rehabilitation

Journal of the American Medical Directors Association

Volumn 17, Issue 9, 2016, Pages 814-820

  Cebron Lipovec, Nanca ^a,b   Schols, Annemie M W J ^b   van den Borst, Bram ^b   Beijers, Rosanne J H C G ^b   Kosten, Tatjana ^a   Omersa, Daniel ^c   Lainscak, Mitja ^d,e  

^a University Clinic of Pulmonary and Allergic Diseases Golnik   (Slovenia)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c NATIONAL INSTITUTE OF PUBLIC HEALTH   (Slovenia)

^d General Hospital Raki an   (Slovenia)

^e UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

cardiometabolic risk; COPD; pulmonary rehabilitation; sarcopenia

Indexed keywords

BIOLOGICAL MARKER; CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

AGED; ARTICLE; BODY COMPOSITION; CARDIOMETABOLIC RISK; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONTROLLED STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; FAT MASS; FEMALE; HUMAN; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PROSPECTIVE STUDY; PULMONARY REHABILITATION; RISK REDUCTION; SARCOPENIA; SKELETAL MUSCLE; WAIST CIRCUMFERENCE; LUNG; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; SEVERITY OF ILLNESS INDEX; SLOVENIA;

AGED; FEMALE; HUMANS; LUNG; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK REDUCTION BEHAVIOR; SARCOPENIA; SEVERITY OF ILLNESS INDEX; SLOVENIA;

EID: 84991824694     PISSN: 15258610     EISSN: 15389375     Source Type: Journal    
DOI: 10.1016/j.jamda.2016.05.002     Document Type: Article

References (40)

1. 1 Beijers, R.J., van den Borst, B., Newman, A.B., et al. A multidimensional risk score to predict all-cause hospitalization in community-dwelling older individuals with obstructive lung disease. J Am Med Dir Assoc 17 (2016), 508–513.
2. 2 Mannino, D.M., Higuchi, K., Yu, T.C., et al. Economic burden of chronic obstructive pulmonary disease by presence of comorbidities. Chest 148 (2015), 138–150.
3. 3 Prince, M.J., Wu, F., Guo, Y., et al. The burden of disease in older people and implications for health policy and practice. Lancet 385 (2015), 549–562.
4. 4 Cruz-Jentoft, A.J., Baeyens, J.P., Bauer, J.M., et al. Sarcopenia: European Consensus on Definition and Diagnosis: Report of the European Working Group on Sarcopenia in Older People. Age Ageing 39 (2010), 412–423.
5. 5 Vanfleteren, L.E., Spruit, M.A., Groenen, M., et al. Clusters of comorbidities based on validated objective measurements and systemic inflammation in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care 187 (2013), 728–735.
6. 6 van de Bool, C., Rutten, E.P., Franssen, F.M., et al. Antagonistic implications of sarcopenia and abdominal obesity on physical performance in COPD. Eur Respir J 46 (2015), 336–345.
7. 7 van de Bool, C., Gosker, H.R., van den Borst, B., et al. Muscle quality is more impaired in sarcopenic patients with chronic obstructive pulmonary disease. J Am Med Dir Assoc 17 (2016), 415–420.
8. 8 Klip, A., Paquet, M.R., Glucose transport and glucose transporters in muscle and their metabolic regulation. Diabetes Care 13 (1990), 228–243.
9. 9 Moon, S.S., Low skeletal muscle mass is associated with insulin resistance, diabetes, and metabolic syndrome in the Korean population: The Korea National Health and Nutrition Examination Survey (KNHANES) 2009–2010. Endoc J 61 (2014), 61–70.
10. 10 Egan, B., Zierath, J.R., Exercise metabolism and the molecular regulation of skeletal muscle adaptation. Cell Metab 17 (2013), 162–184.
11. 11 Spruit, M.A., Singh, S.J., Garvey, C., et al. An official American Thoracic Society/European Respiratory Society statement: Key concepts and advances in pulmonary rehabilitation. Am J Respir Crit Care 188 (2013), e13–e64.
12. 12 Zupanic, E., Zivanovic, I., Kalisnik, J.M., et al. The effect of 4-week rehabilitation on heart rate variability and QTC interval in patients with chronic obstructive pulmonary disease. COPD 11 (2014), 659–669.
13. 13 Miller, M.R., Crapo, R., Hankinson, J., et al. General considerations for lung function testing. Eur Respir J 26 (2005), 153–161.
14. 14 Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease 2011. Available at: http://www.goldcopd.org/guidelines-global-strategy-for-diagnosis-management.html. Accessed January 6, 2016.
15. 15 Alberti, K.G., Zimmet, P., Shaw, J., Metabolic syndrome—a new world-wide definition. A consensus statement from the International Diabetes Federation. Diabetic Med 23 (2006), 469–480.
16. 16 2013 practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC): ESH/ESC Task Force for the Management of Arterial Hypertension. J Hypertens 31 (2013), 1925–1938.
17. 17 ATS statement: Guidelines for the six-minute walk test. Am J Respir Crit Care 166 (2002), 111–117.
18. 18 Holland, A.E., Hill, C.J., Rasekaba, T., et al. Updating the minimal important difference for six-minute walk distance in patients with chronic obstructive pulmonary disease. Arch Phys Med Rehab 91 (2010), 221–225.
19. 19 Jones, P.W., St. George's respiratory questionnaire: MCID. COPD 2 (2005), 75–79.
20. 20 Matthews, D.R., Hosker, J.P., Rudenski, A.S., et al. Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28 (1985), 412–419.
21. 21 Stephens, F.B., Chee, C., Wall, B.T., et al. Lipid-induced insulin resistance is associated with an impaired skeletal muscle protein synthetic response to amino acid ingestion in healthy young men. Diabetes 64 (2015), 1615–1620.
22. 22 Murton, A.J., Marimuthu, K., Mallinson, J.E., et al. Obesity appears to be associated with altered muscle protein synthetic and breakdown responses to increased nutrient delivery in older men, but not reduced muscle mass or contractile function. Diabetes 64 (2015), 3160–3171.
23. 23 Wells, C.E., Polkey, M.I., Baker, E.H., Insulin resistance is associated with skeletal muscle weakness in COPD. Respirology 21 (2016), 689–696.
24. 24 van den Borst, B., Gosker, H.R., Wesseling, G., et al. Low-grade adipose tissue inflammation in patients with mild-to-moderate chronic obstructive pulmonary disease. Am J Clin Nutr 94 (2011), 1504–1512.
25. 25 Eker, S., Ayaz, L., Tamer, L., et al. Leptin, visfatin, insulin resistance, and body composition change in chronic obstructive pulmonary disease. Scand J Clin Lab Inv 70 (2010), 40–44.
26. 26 Jelleyman, C., Yates, T., O'Donovan, G., et al. The effects of high-intensity interval training on glucose regulation and insulin resistance: A meta-analysis. Obes Rev 16 (2015), 942–961.
27. 27 Davidson, L.E., Hudson, R., Kilpatrick, K., et al. Effects of exercise modality on insulin resistance and functional limitation in older adults: A randomized controlled trial. Arch Intern Med 169 (2009), 122–131.
28. 28 Sigal, R.J., Kenny, G.P., Boule, N.G., et al. Effects of aerobic training, resistance training, or both on glycemic control in type 2 diabetes: A randomized trial. Ann Intern Med 147 (2007), 357–369.
29. 29 Mossmann, M., Wainstein, M.V., Goncalves, S.C., et al. HOMA-IR is associated with significant angiographic coronary artery disease in non-diabetic, non-obese individuals: A cross-sectional study. Diabetolmetab Syndr, 7, 2015, 100.
30. 30 Franssen, F.M., Sauerwein, H.P., Ackermans, M.T., et al. Increased postabsorptive and exercise-induced whole-body glucose production in patients with chronic obstructive pulmonary disease. Metab Clin Exp 60 (2011), 957–964.
31. 31 Simoneau, J.A., Kelley, D.E., Altered glycolytic and oxidative capacities of skeletal muscle contribute to insulin resistance in NIDDM. J Appl Physiol (1985) 83 (1997), 166–171.
32. 32 Skyba, P., Ukropec, J., Pobeha, P., et al. Metabolic phenotype and adipose tissue inflammation in patients with chronic obstructive pulmonary disease. Mediators Inflamm, 2010, 2010, 173498.
33. 33 Franssen, F.M., Broekhuizen, R., Janssen, P.P., et al. Effects of whole-body exercise training on body composition and functional capacity in normal-weight patients with COPD. Chest 125 (2004), 2021–2028.
34. 34 Gale, N.S., Duckers, J.M., Enright, S., et al. Does pulmonary rehabilitation address cardiovascular risk factors in patients with COPD?. BMC Pulm Med, 11, 2011, 20.
35. 35 Reed, R.M., Iacono, A., DeFilippis, A., et al. Advanced chronic obstructive pulmonary disease is associated with high levels of high-density lipoprotein cholesterol. J Heart Lung Transplant 30 (2011), 674–678.
36. 36 Out, C., Dikkers, A., Laskewitz, A., et al. Prednisolone increases enterohepatic cycling of bile acids by induction of ASBT and promotes reverse cholesterol transport. J Hepatol 61 (2014), 351–357.
37. 37 Silbernagel, G., Genser, B., Drechsler, C., et al. HDL cholesterol, apolipoproteins, and cardiovascular risk in hemodialysis patients. Clin J Am Soc Nephrol 26 (2015), 484–492.
38. 38 Wilkins, J.T., Ning, H., Stone, N.J., et al. Coronary heart disease risks associated with high levels of HDL cholesterol. J Am Heart Assoc, 3, 2014, e000519.
39. 39 Spruit, M.A., Augustin, I.M., Vanfleteren, L.E., et al. Differential response to pulmonary rehabilitation in COPD: Multidimensional profiling. Eur Respir J 46 (2015), 1625–1635.
40. 40 Ambrosino, N., Clini, E.M., Response to pulmonary rehabilitation: Toward personalised programmes?. Eur Respir J 46 (2015), 1538–1540.